Form 4: Royalty Pharma Executive Acquires Shares Through Equity Performance Award Settlement

George W. Lloyd, EVP of Investments & CLO at Royalty Pharma plc, acquired 48,646 Class A Ordinary Shares through the settlement of Equity Performance Awards on May 8, 2025.

Summary

• On May 8, 2025, George W. Lloyd, an Executive Vice President at Royalty Pharma plc, acquired 48,646 Class A Ordinary Shares.
• The acquisition was made through the settlement of Equity Performance Awards, as per Rule 16b-3.
• The shares were acquired at a price of $0.
• Following the transaction, Lloyd directly owns 48,646 Class A Ordinary Shares.
• Lloyd also indirectly owns shares through various entities, including GWL 2023 G HoldCo LLC (3,000 shares), an IRA (273,960 shares), GWL 2013 NG, LLC (495,860 shares), GWL 2014 G, LLC (220,000 shares), GWL 2020 G, LLC (52,000 shares), GWL 2021 G, LLC (28,000 shares), and through a spouse (4,011.19 shares).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The acquisition of shares by an executive is generally viewed as a positive sign, but it's part of a pre-existing compensation plan.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. It provides transparency to the market regarding insider transactions.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals executive confidence, but the overall impact is minimal.

Key Dates

Keywords

Royalty Pharma, RPRX, George W. Lloyd, Equity Performance Awards, Class A Ordinary Shares, Beneficial Ownership, Form 4, SEC Filing